AU2017269115B2 - Mixtures of antibodies - Google Patents

Mixtures of antibodies Download PDF

Info

Publication number
AU2017269115B2
AU2017269115B2 AU2017269115A AU2017269115A AU2017269115B2 AU 2017269115 B2 AU2017269115 B2 AU 2017269115B2 AU 2017269115 A AU2017269115 A AU 2017269115A AU 2017269115 A AU2017269115 A AU 2017269115A AU 2017269115 B2 AU2017269115 B2 AU 2017269115B2
Authority
AU
Australia
Prior art keywords
antibody
antibodies
human
binds
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017269115A
Other languages
English (en)
Other versions
AU2017269115A1 (en
Inventor
Zhi Liu
Martin J. PENTONY
Wei Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Puget Sound Biotherapeutics Corp
Original Assignee
Qilu Puget Sound Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Puget Sound Biotherapeutics Corp filed Critical Qilu Puget Sound Biotherapeutics Corp
Publication of AU2017269115A1 publication Critical patent/AU2017269115A1/en
Application granted granted Critical
Publication of AU2017269115B2 publication Critical patent/AU2017269115B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017269115A 2016-05-26 2017-05-02 Mixtures of antibodies Expired - Fee Related AU2017269115B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342167P 2016-05-26 2016-05-26
US62/342,167 2016-05-26
PCT/US2017/030676 WO2017205014A1 (en) 2016-05-26 2017-05-02 Mixtures of antibodies

Publications (2)

Publication Number Publication Date
AU2017269115A1 AU2017269115A1 (en) 2018-11-29
AU2017269115B2 true AU2017269115B2 (en) 2024-06-20

Family

ID=58709577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017269115A Expired - Fee Related AU2017269115B2 (en) 2016-05-26 2017-05-02 Mixtures of antibodies

Country Status (7)

Country Link
US (2) US11130808B2 (enExample)
EP (1) EP3463451A1 (enExample)
JP (2) JP7301540B2 (enExample)
CN (1) CN109475627B (enExample)
AU (1) AU2017269115B2 (enExample)
CA (1) CA3025162A1 (enExample)
WO (1) WO2017205014A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
JP6954842B2 (ja) 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
TW201834688A (zh) * 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
EP3431105B1 (en) 2017-03-29 2020-01-01 Shionogi&Co., Ltd. Medicinal composition for treating cancer
UA128389C2 (uk) * 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
JP2019151621A (ja) * 2018-02-28 2019-09-12 学校法人藤田学園 Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
WO2020180811A1 (en) 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
AU2020336440A1 (en) 2019-08-30 2022-03-24 Qilu Puget Sound Biotherapeutics Corporation Anti-CD20 antibodies, anti-CD37 antibodies, and mixtures thereof
US20230265134A1 (en) * 2019-09-30 2023-08-24 Adimab, Llc Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
WO2021126538A1 (en) * 2019-12-17 2021-06-24 Phanes Therapeutics, Inc. Bispecific antibodies with alternatively matched interchain cycteines and uses thereof
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
CA3170741A1 (en) * 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
EP4200338A1 (en) * 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
MX2023002511A (es) * 2020-08-28 2023-04-20 Harbour Biomed Us Inc Anticuerpo anti-ccr8 y aplicacion del mismo.
CN114437226A (zh) * 2020-11-05 2022-05-06 杭州菁因康生物科技有限公司 制备双特异性抗体的方法
EP4294531A4 (en) * 2021-02-18 2025-07-16 Qilu Puget Sound Biotherapeutics Corp COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES
CN112961245B (zh) * 2021-02-24 2023-07-25 重庆精准生物技术有限公司 一种靶向cd96的双特异性抗体及其制备方法和用途
MX2023012324A (es) * 2021-04-20 2023-10-30 Amgen Inc Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
US20240182576A1 (en) * 2021-04-23 2024-06-06 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
US20230048743A1 (en) * 2021-07-12 2023-02-16 Genentech Inc. Structures for Reducing Antibody-Lipase Binding
IL309856A (en) 2021-07-14 2024-02-01 Genentech Inc Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use
JP2024527582A (ja) * 2021-07-19 2024-07-25 中外製薬株式会社 融合ポリペプチドを用いるプロテアーゼ媒介性の標的特異的サイトカイン送達
CN118339188A (zh) * 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
CN118660720A (zh) * 2022-02-22 2024-09-17 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN118946366A (zh) * 2022-04-13 2024-11-12 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN119300862A (zh) * 2022-06-28 2025-01-10 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN119300863A (zh) * 2022-06-30 2025-01-10 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN119604525A (zh) 2022-07-22 2025-03-11 信达生物制药(苏州)有限公司 促进多特异性抗体的重链和轻链同源配对的突变体
EP4644548A1 (en) 2022-12-27 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide with controlled association
EP4655595A1 (en) * 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2025059037A1 (en) * 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025117485A1 (en) * 2023-11-29 2025-06-05 Qilu Puget Sound Biotherapeutics Corporation Anti-il33 and anti-tslp antibodies, and mixtures
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
CA2512647C (en) * 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
PL2132229T3 (pl) * 2007-03-01 2016-12-30 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
PT2235064E (pt) * 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
EP3153524B1 (en) 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
CN102365296A (zh) * 2009-01-26 2012-02-29 根马布股份公司 用于生成抗体混合物的方法
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
US20130177555A1 (en) 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
EP2686682A4 (en) 2011-03-11 2015-03-11 Amgen Inc METHOD FOR CORRELATED MUTATION ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
BR112013023653A2 (pt) 2011-03-17 2016-12-13 Univ Ramot anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
PL2794905T3 (pl) * 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
CN110669136A (zh) * 2012-11-05 2020-01-10 全药工业株式会社 抗体或抗体组合物的制备方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
DK2927321T3 (da) 2012-11-27 2021-03-15 Univ Ajou Ind Academic Coop Found Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf
KR102545617B1 (ko) 2012-11-28 2023-06-20 자임워크스 비씨 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
KR101813708B1 (ko) 2013-03-13 2017-12-29 (주) 아이벤트러스 소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법
EP2970435B1 (en) 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
KR20250152665A (ko) 2013-07-31 2025-10-23 암젠 인크 Ｆc-함유 폴리펩타이드의 안정화
US10684289B2 (en) 2013-12-09 2020-06-16 Adimab, Llc Polyclonal mixtures of antibodies, and methods of making and using them
EP3143043B1 (en) * 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
AU2017356860A1 (en) * 2016-11-08 2019-05-16 Qilu Puget Sound Biotherapeutics Corporation Anti-PD1 and anti-CTLA4 antibodies

Also Published As

Publication number Publication date
CN109475627A (zh) 2019-03-15
US20190248899A1 (en) 2019-08-15
CA3025162A1 (en) 2017-11-30
WO2017205014A1 (en) 2017-11-30
EP3463451A1 (en) 2019-04-10
JP2022010244A (ja) 2022-01-14
JP2019520063A (ja) 2019-07-18
CN109475627B (zh) 2023-01-06
US20220073615A1 (en) 2022-03-10
AU2017269115A1 (en) 2018-11-29
JP7301540B2 (ja) 2023-07-03
US11130808B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
AU2017269115B2 (en) Mixtures of antibodies
AU2017248671B2 (en) Trispecific and/or trivalent binding proteins
AU2017296095C1 (en) Multispecific antibodies against CD40 and CD137
AU2019200346B2 (en) Compositions and methods of use for augmented immune response and cancer therapy
AU2017255970B2 (en) Bispecific antibodies targeting EGFR and HER2
AU2016383475B2 (en) Variable regions for NKp46 binding proteins
CN110312523B (zh) 抗pd1和抗ctla4抗体
AU2018284303B2 (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
AU2017237376B2 (en) Protease-activated T cell bispecific molecules
AU2017384687B2 (en) Bispecific anti-TNF-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2016296321B2 (en) Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders
AU2014222779B2 (en) Bispecific T cell activating antigen binding molecules
AU2017256786B2 (en) Binding molecules specific for FcγGamma RIIA and uses thereof
AU2017236183B2 (en) Binding molecules to CD38 and PD-L1
JP2017532290A (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
AU2021301921B2 (en) Bispecific antibody and use thereof
KR20210076918A (ko) 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
JP2021532085A (ja) ＣＴＬＡ−４を標的とする改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
EP4025598A1 (en) Proteins comprising t-cell receptor constant domains
JP2021531756A (ja) ＣＣＲ４を標的指向する改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法
JP2021530989A (ja) ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
AU2020381735B2 (en) Molecule capable of binding to human 4-1BB, and application of molecule
WO2023108115A1 (en) Ph-selective antibody fc domains
TW202306584A (zh) 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
AU2021410290A9 (en) Pharmaceutical composition for treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee